Correction to: European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention
Abstract Following publication of the original article [1], the authors notified us of some misreported data due to the publication of the EVOLVE-2 trial (Cephalalgia. 2018;38:1442–1454), which substantially changed the level of evidence of galcanezumab for the prevention of episodic migraine. All c...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2019-05-01
|
| Series: | The Journal of Headache and Pain |
| Online Access: | http://link.springer.com/article/10.1186/s10194-019-0972-5 |
| id |
doaj-55c34ad2b80d49b6aa017cb2c0459e68 |
|---|---|
| record_format |
Article |
| spelling |
doaj-55c34ad2b80d49b6aa017cb2c0459e682020-11-25T03:23:36ZengBMCThe Journal of Headache and Pain1129-23691129-23772019-05-0120112410.1186/s10194-019-0972-5Correction to: European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine preventionSimona Sacco0Lars Bendtsen1Messoud Ashina2Uwe Reuter3Gisela Terwindt4Dimos-Dimitrios Mitsikostas5Paolo Martelletti6Neuroscience Section, Department of Applied Clinical Sciences and Biotechnology, University of L’AquilaDepartment of Neurology, Danish Headache Center, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of CopenhagenDepartment of Neurology, Danish Headache Center, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of CopenhagenDepartment of Neurology, Charité Universitätsmedizin BerlinDepartment of Neurology, Leiden University Medical Center1st Department of Neurology, National and Kapodistrian University of AthensDepartment of Clinical and Molecular Medicine, Sapienza UniversityAbstract Following publication of the original article [1], the authors notified us of some misreported data due to the publication of the EVOLVE-2 trial (Cephalalgia. 2018;38:1442–1454), which substantially changed the level of evidence of galcanezumab for the prevention of episodic migraine. All changes are marked in bold and with red in Figure 1 and Figure 2. Please note that the final recommendations remain unchanged.http://link.springer.com/article/10.1186/s10194-019-0972-5 |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Simona Sacco Lars Bendtsen Messoud Ashina Uwe Reuter Gisela Terwindt Dimos-Dimitrios Mitsikostas Paolo Martelletti |
| spellingShingle |
Simona Sacco Lars Bendtsen Messoud Ashina Uwe Reuter Gisela Terwindt Dimos-Dimitrios Mitsikostas Paolo Martelletti Correction to: European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention The Journal of Headache and Pain |
| author_facet |
Simona Sacco Lars Bendtsen Messoud Ashina Uwe Reuter Gisela Terwindt Dimos-Dimitrios Mitsikostas Paolo Martelletti |
| author_sort |
Simona Sacco |
| title |
Correction to: European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention |
| title_short |
Correction to: European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention |
| title_full |
Correction to: European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention |
| title_fullStr |
Correction to: European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention |
| title_full_unstemmed |
Correction to: European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention |
| title_sort |
correction to: european headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention |
| publisher |
BMC |
| series |
The Journal of Headache and Pain |
| issn |
1129-2369 1129-2377 |
| publishDate |
2019-05-01 |
| description |
Abstract Following publication of the original article [1], the authors notified us of some misreported data due to the publication of the EVOLVE-2 trial (Cephalalgia. 2018;38:1442–1454), which substantially changed the level of evidence of galcanezumab for the prevention of episodic migraine. All changes are marked in bold and with red in Figure 1 and Figure 2. Please note that the final recommendations remain unchanged. |
| url |
http://link.springer.com/article/10.1186/s10194-019-0972-5 |
| work_keys_str_mv |
AT simonasacco correctiontoeuropeanheadachefederationguidelineontheuseofmonoclonalantibodiesactingonthecalcitoningenerelatedpeptideoritsreceptorformigraineprevention AT larsbendtsen correctiontoeuropeanheadachefederationguidelineontheuseofmonoclonalantibodiesactingonthecalcitoningenerelatedpeptideoritsreceptorformigraineprevention AT messoudashina correctiontoeuropeanheadachefederationguidelineontheuseofmonoclonalantibodiesactingonthecalcitoningenerelatedpeptideoritsreceptorformigraineprevention AT uwereuter correctiontoeuropeanheadachefederationguidelineontheuseofmonoclonalantibodiesactingonthecalcitoningenerelatedpeptideoritsreceptorformigraineprevention AT giselaterwindt correctiontoeuropeanheadachefederationguidelineontheuseofmonoclonalantibodiesactingonthecalcitoningenerelatedpeptideoritsreceptorformigraineprevention AT dimosdimitriosmitsikostas correctiontoeuropeanheadachefederationguidelineontheuseofmonoclonalantibodiesactingonthecalcitoningenerelatedpeptideoritsreceptorformigraineprevention AT paolomartelletti correctiontoeuropeanheadachefederationguidelineontheuseofmonoclonalantibodiesactingonthecalcitoningenerelatedpeptideoritsreceptorformigraineprevention |
| _version_ |
1724605493610020864 |